Latest Racing News

Critical Resources Limited has validated its amorphous solid-state electrolyte, demonstrating stable lithium-metal interface performance over 1,200 hours and efficient ionic conductivity at room temperature, marking a significant step in solid-state battery development.

AML3D has landed a nearly $10 million order for four ARCEMY X 6700 systems from Newport News Shipbuilding, expanding its footprint in the US defence manufacturing sector.

Klevo Rewards’ subsidiary Fly Wallet has secured approval to join the SWIFT network, marking a key step in expanding its digital payments and rewards platform across the Asia-Pacific region.

OD6 Metals has significantly expanded its claim holdings around the Quinn Fluorspar Project in Nevada, securing promising new exploration targets including the large Dresser epithermal alteration zone. This move strengthens its position in a critical mineral district vital to US supply chains.

Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.

iCandy Interactive is exploring a US listing for its subsidiary Lemon Sky Studios to unlock shareholder value, while facing a likely ASX delisting due to audit delays. The company also plans a capital raise to support these initiatives.

Belararox Limited has strategically expanded its Argentine copper exploration by acquiring the El Faro tenement adjacent to its Toro South target, adding 22km² of promising ground to its TMT Project. This move strengthens its position amid ongoing drilling targeting a potentially significant copper system.

Bayan Mining has secured U.S. Bureau of Land Management approval for an expanded drilling program at its Desert Star rare earth project, enabling deeper exploration of high-grade targets near the Mountain Pass mine.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

Ainsworth Game Technology reported a 10% revenue increase to AUD 290.8 million for 2025 but posted a net loss of AUD 19.2 million, driven by a significant goodwill impairment and foreign currency headwinds. The company’s strategic investments and market challenges set the stage for a pivotal year ahead.